BioCryst Pharmaceuticals BCRX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 97.8%+0.8pp | 97.8%+0.5pp | 97.4%-0.7pp | 97%-1.5pp | 96.9%-1.7pp | |
| Operating margin | -43.1%-49.7pp | 39%+39.5pp | 12.7%+22.6pp | 9.7%+25.5pp | 6.6%+31.9pp | |
| Net margin | -51.7%-41.1pp | 30.2%+49.9pp | -1.5%+28.5pp | -6.4%+31.8pp | -10.6%+48.1pp | |
| EBITDA margin | -42.9%-49.7pp | 39.1%+39.4pp | 12.9%+22.4pp | 10%+25.3pp | 6.8%+31.7pp | |
| Returns | ||||||
| Return on assets | -96.9%-85.6pp | 52.5%+70.2pp | -1.9%+22.5pp | -7.7%+21.4pp | -11.3%+31.4pp | |
| Efficiency | ||||||
| Asset turnover | 1.9×+0.8× | 1.7×+0.8× | 1.3×+0.5× | 1.2×+0.4× | 1.1×+0.3× | |
| Inventory turnover | 0.7×— | 0.8×— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 1.9×-1.0× | 2.1×-0.6× | 1.9×-0.9× | 2.2×-0.6× | 2.9×-0.8× | |
| Quick ratio | 1.8×-1.0× | 1.9×-0.5× | 1.7×-0.9× | 2.1×-0.5× | 2.8×-0.7× | |
| Cash ratio | 0.9×+0.1× | 0.5×-0.2× | 0.4×-0.2× | 0.5×-0.1× | 0.8×+0.1× | |
| Leverage | ||||||
| Debt-to-assets | 0.9×+0.2× | 0×-0.6× | 0.5×-0.2× | 0.6×-0.1× | 0.7×0.0× | |
| Interest coverage | -5.1×-5.4× | 4.3×+4.3× | 0.9×+1.3× | 0.6×+1.2× | 0.3×+1.2× | |
| Per Share | ||||||
| Book value per share | -$2.29-8.9% | -$0.55+76.3% | -$1.76+22.1% | -$1.92+16.8% | -$2.10+9.1% | |
| Valuation | ||||||
| Market capitalization | $2.39B+52.3% | $1.64B+5.5% | $1.59B+1.3% | $2.08B+62.9% | $1.57B+49.7% | |
| Enterprise value | $2.63B+46.7% | $1.57B-12.1% | $1.72B-4.9% | $2.25B+47.3% | $1.79B+39.1% | |
| Price / sales | 2.7×-0.4× | 1.9×-1.6× | 2.7×-1.2× | 3.7×+0.4× | 3.1×+0.2× | |
| EV / sales | 3×-0.6× | 1.8×-2.2× | 2.9×-1.5× | 4×0.0× | 3.6×-0.1× | |
| Earnings yield | -19.2%-15.8pp | 16.1%+21.8pp | -0.6%+7.3pp | -1.7%+9.7pp | -3.4%+16.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BioCryst Pharmaceuticals's profit margins?
- BioCryst Pharmaceuticals (BCRX) runs a 97.8% gross margin and a -43.1% operating margin, with a -51.7% net margin.
- Where do BioCryst Pharmaceuticals's ratios come from?
- Every ratio is computed from BioCryst Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
